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Abstract
Background
Measuring factors influencing time to presentation is important in developing and evaluating
interventions to promote timely cancer diagnosis, yet there is a lack of validated, culturally
relevant measurement tools. This study aimed to develop and validate the African Women
Awareness of CANcer (AWACAN) tool to measure awareness of breast and cervical cancer
in Sub-Saharan Africa (SSA).
Methods
Development of the AWACAN tool followed 4 steps: 1) Item generation based on existing
measures and relevant literature. 2) Refinement of items via assessment of content and
face validity using cancer experts’ ratings and think aloud interviews with community partici-
pants in Uganda and South Africa. 3) Administration of the tool to community participants,
university staff and cancer experts for assessment of validity using test-retest reliability
(using Intra-Class Correlation (ICC) and adjusted Kappa coefficients), construct validity
(comparing expert and community participant responses using t-tests) and internal reliability
(using the Kuder-Richarson (KR-20) coefficient). 4) Translation of the final AWACAN tool
into isiXhosa and Acholi.
Results
ICC scores indicated good test-retest reliability (� 0.7) for all breast cancer knowledge
domains and cervical cancer risk factor and lay belief domains. Experts had higher
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knowledge of breast cancer risk factors (p < 0.001), and cervical cancer risk factors (p =
0.003) and symptoms (p = 0.001) than community participants, but similar knowledge of
breast cancer symptoms (p = 0.066). Internal reliability for breast cancer risk factors, lay
beliefs and symptom and cervical cancer symptom subscales was good with KR-20 values
> 0.7, and lower (0.6) for the cervical cancer risk subscale.
Conclusion
The final AWACAN tool includes items on socio-demographic details; breast and cervical
cancer symptom awareness, risk factor awareness, lay beliefs, anticipated help-seeking
behaviour; and barriers to seeking care. The tools showed evidence of content, face, con-
struct and internal validity and test-retrest reliability and are available for use in SSA in three
languages.
Introduction
Breast and cervical cancer are the leading causes of cancer morbidity and mortality in women
in Sub-Saharan Africa (SSA). Breast cancer is the most commonly diagnosed cancer among
women in SSA, whilst cervical cancer remains the leading cause of cancer death [1]. Most SSA
countries do not have cervical or breast cancer screening programs and the majority of cancers
(85–90%) present symptomatically and at an advanced stage [2].
Studies have shown that for symptomatic breast cancer, a shorter time between recognition
of symptoms by women and first medical consultation is associated with early stage disease,
and better breast cancer survival [3–6]. Further, a substantial proportion of advanced stage
diagnosis of poorly differentiated breast cancer cases could be avoided if patients had pre-
sented within one month of detecting symptoms [4]. For both breast and cervical cancer there
are often subtle but important symptoms in early stage disease, yet women may misinterpret
these symptoms or wait until symptoms (and disease) progress before they seek medical atten-
tion [7–10]. Research outside SSA has indicated that cancer symptom awareness among the
general population can be low [11–12], and that interventions to increase awareness lead to
better outcomes. For example, in Malaysia, raising public awareness of symptoms has been
associated with earler diagnosis of cervical cancer [13].
For people with potential symptoms of cancer, the pathway to cancer diagnosis is complex
and influenced by many factors such as symptom and risk awareness, beliefs and barriers to
accessing care [9,10,14–18]. Measuring these factors is important in developing and evaluating
interventions to promote timely cancer diagnosis. A recent scoping study highlighted the need
for local research arising from low-and middle-income countries to adequately address breast
and cervical cancer prevention and control [19].
Although a few studies have reported on breast and cervical cancer symptom awareness,
risk perception and help-seeking behavior in African settings [9,10,20,21], measurement and
comparison is hampered by the lack of validated, culturally relevant measurement tools. The
Cancer Awareness Measure (CAM) and the Awareness and Beliefs about Cancer (ABC) tools,
developed and validated in the UK to reliably assess cancer awareness in the general public, are
questionnaires that include generic and cancer site specific modules [22–26]. The CAM and
ABC tools could be of value beyond the UK, but as they were developed in a very different cul-
tural setting they need to be adapted and validated for use in SSA. A Kenyan research team
adapted the Breast Cancer Awareness Measurement (BCAM) for local use and reported on
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validity testing of two of the tool domains (symptom awareness and barriers to screening)
[27]. The team reported good content validity and internal reliability for the two domains,
demonstrating that the BCAM could be adapted for use in African populations, but they also
recommended further validation. The aim of the current study was to develop and validate an
African Women’s Awareness of CANcer (AWACAN) tool to measure awareness of symptoms
and risk factor for breast and cervical cancer, lay beliefs, confidence in appraising potential
symptoms, help-seeking behavior and barriers to health care.
Methods
The four step processes of 1) generating tool items, 2) refining and 3) validating the English
version of the AWACAN tool and, 4) developing local language versions of the tool are
described below. The outcomes of Step 3 are presented in the results section. Ethics approval
for the study was obtained from University of Cape Town, Faculty of Health Sciences Human
Research Ethics Committee (HREC 544/2016), the Lacor Hospital Institutional Research Eth-
ics Committee (LHIREC 027/11/2016) and the Ugandan National Council of Science and
Technology (UNCST 194/212/01). Written informed consent was obtained from all partici-
pants. Permission to access health facilities was obtained from all relevant local health authori-
ties. Permission to conduct interviews with non-medical university staff was obtained from
the institutional human resource department.
Step 1: Generating items for the AWACAN tool
Items to assess breast and cervical cancer symptom and risk factor awareness and help-seeking
behavior were generated by reviewing the UK (BCAM) and Cervical Cancer Awareness Mea-
surement (CCAM) tools, the ABC tool, and studies conducted in Africa that used these or other
tools to measure constructs of interest to our study [10, 25–27]. Items relating to overall cancer
awareness (not specific to breast or cervical cancer) and awareness of screening programs were
excluded as this was not the focus on our study. The multi-disciplinary research team reviewed
the list of items, making changes so that the terminology would be applicable to the African set-
ting. A first version of the AWACAN tool was drafted and consisted of a total of 131 items: 13
socio-demographic; 57 breast cancer; 42 cervical cancer and; 19 barriers to seeking health care
questions. The list of variables included; having heard of or knowing someone with breast or
cervical cancer; knowledge of age-related risk; knowledge of risk factors and symptoms of breast
and cervical cancer (evidence-based); and risk lay beliefs such as exposure to an unhygienic
environment, placing objects in undergarments and witchcraft. Based on experiences with the
use of BCAM in Kenya [27], we chose to commission images of breast cancer signs on dark
skinned women, developed by a graphic designer in consultation with the breast cancer surgeon
on the team (LC). Items also assessed confidence in detecting breast or cervical cancer symp-
toms. Help-seeking behavior variables assessed whether participants would ignore symptoms,
try self-medication, inform a friend/relative, visit a traditional healer and visit a medical facility.
Anticipated time to presentation to medical facilities and traditional healers was measured on a
scale from immediately to more than 1 year. Barriers to seeking care were measured in terms of
emotional, practical and service related barriers. The AWACAN tool was designed to be deliv-
ered via a structured interview rather than self-completed questionnaire.
Step 2: Refinement of items for the AWACAN tool
To assess content validity. A group of cancer experts based in SSA (n = 48) were invited
to complete an anonymous online survey and score the AWACAN tool items in terms of clar-
ity and relevance [(1(poor) - 4 (excellent)], provide reasons for any item scoring < 3, and
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identify missing items. The experts included breast or cervical cancer health professionals, epi-
demiologists and public health researchers and were identified from peer-reviewed literature,
websites of relevant academic and research organizations and through contacts of research
team members. A content validity index [(CVI) number of raters giving a score of�3/total
number of raters] was calculated for each tool item [28]. Any item with a CVI >78% was
regarded as having an adequate CVI as recommended by Lynn et al. [28]. In total 25 experts
completed the online survey.
To assess face validity. Cognitive interviews using think-aloud methodology [29–30]
were conducted with English-speaking women aged 18 years and older to assess interpretation
and understanding of the tool items. Participants, excluding women with a history of breast or
cervical cancer, were recruited from primary care clinics in urban primary health care clinics
in South Africa (n = 10) and Uganda (n = 10) and asked to think aloud as they responded to
the structured interview. Interviews were transcribed verbatim and analysed to identify areas
of ambiguity and items causing distress.
Findings from both the cancer expert review and the cognitive interviews were reviewed
and tool items revised where necessary. This resulted in: items being deleted; questions being
reworded/rephrased for clarity; definitions being added for poorly understood terms and; a
revision of response options for some questions. Items on age-related risk factors (e.g. Do you
think that a woman younger than you is more likely to get breast cancer?) were deleted as they
were poorly understood by participants and all had a low CVI. An item on participant’s reli-
gion was deleted as it had a low CVI (0.56) with cancer experts noting that it could be viewed
as being judgemental. Five questions were identified as being redundant as they were covered
elsewhere in the questionnaire and were removed. Explanations were added for the terms
“hormone replacement therapy” and “menopause” as these were poorly understood by
women. All questions with Likert response options had a low CVI (< 78%) and were poorly
understood by women during the cognitive interviews. Options for these questions were
revised. For example, the question “How confident are you that you would notice a change in
your breast?” with response options a. very confident b. fairly confident c. slightly confident
and d. not confident at all was changed to “Are you confident that you would notice a change
in your breast?” with response options a. yes b. no c. not sure.
The refinement process resulted in a second version of the AWACAN tool with a total of
123 items: 12 socio-demographic questions; 53 breast cancer symptom,risk factor, confidence
and help-seeking questions; 39 cervical cancer symptom, risk factor, confidence and help-seek-
ing questions and 19 items on barriers to seeking care.
Step 3: Validation of the AWACAN tool
Participants and procedure. Three groups of participants completed the second version
of the AWACAN tool:
i. Community participants: Women aged� 18 years and able to speak and understand
English were recruited from primary care clinics at the sites used for the cognitive interviews
described above. English proficiency was assessed by a trained interviewer during the pro-
cess of providing study information and obtaining informed consent. Participants that were
unable to understand and speak English were excluded. Women were stratified by age dur-
ing recruitment to ensure representation by older (� 50 years) and younger (< 50 years)
participants. Trained field workers administered the tool to participants.
ii. Cancer experts: Experts who participated in the content validaty exercise (Step 2A) were
invited to complete an on-line version of the tool.
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iii. A convenience sample of non-medical university staff: aged 18 to 65 years were recruited
from the University of Cape Town. A trained interviewer administered the tool on two
occasions, two weeks apart. Participants were stratified by age (� 50 years and< 50 years).
Data management. All data was entered into Qualtrics and analysed using STATA (Ver-
sion 13.0). Scores for risk factor knowledge and symptom awareness were calculated with each
correct answer to the evidence-based questions in the closed/prompted sections scoring 1
point. Lay beliefsthat were correctly identified as not being a risk factor scored 1 point.
The revised 123-item tool was assessed in terms of indicators of test-retest reliability, con-
struct validity and internal reliability.
Test-rest reliability analysis. For categorical variables related to awareness (having heard
of or knowing someone with relevant cancer), help-seeking behaviour and confidence test-
retest reliability was calculated using the Brennan and Prediger prevalence-adjusted and bias-
adjusted Kappa. Adjusted Kappas were calculated as the unadjusted Cohen Kappa is preva-
lence dependant and misleading when ratings fall into a single category [31,32]. We present
both adjusted Kappa and Cohen’s Kappa values, as adjusted Kappa presented alone can be dif-
ficult to interpret. Kappa coefficients were interpreted as follows: <0.00 as poor; 0.00–0.20 as
slight; 0.21–0.40 as fair; 0.41–0.60 as moderate; 0.61–0.80 as substantial and 0.81–1.0 as almost
perfect agreement [33].
For knowledge domains, test-retest reliability was assessed by comparing the mean test and
retest scores of the non-medical staff, using the intra-class correlation coefficient (ICC) with
values below 0.5 indicating poor reliability, between 0.5 and 0.75 moderate reliability, between
0.76 and 0.9 good reliability, and above 0.9 excellent reliability [34].
Construct validity analysis. Construct validity was assessed by comparing knowledge
scores between the cancer experts and community participant group using t-tests. We hypoth-
esized that if the tool had construct validity then cancer experts would have significantly
(p<0.05) higher awareness compared to community respondents.
Internal reliability analysis. Internal reliability for the risk factor and symptom knowl-
edge constructs were assessed using the Kuder-Richarson (KR-20) coefficient of reliability and
the item-to-total correlation coefficients. A KR-20 of> 0.7 was considered to indicate good
internal reliability [35,36]. For the item-to-total correlation, a value greater than 0.2 was an
indicator that an item was related to the overall scale [22,37].
Sample size. Typically, studies measuring internal reliability are based on the assumption
that the number of respondents should exceed the number of items by 2 to 20 subjects per
item, with a minimum of 100 subjects to ensure stability of the variance-covariance matrix
[38]. Our sample size was based on an initial anticipated 60-item per cancer tool. Applying a
3:1 subject to item ratio we aimed to recruit a total of 180 to ensure a reasonably precise esti-
mate the KR-20.
Step 4: Development of the local language versions of the tool
The English version of the final AWACAN tool was translated into isiXhosa (the 2nd common-
est of 11 official languages in SA and Acholi (spoken in Northern Uganda and parts of Kenya
and Tanzania) by Acholi and isiXhosa native speakers, and back translated into English to
ensure comparability [39,40]. Forward and backward translations were also undertaken by a
university-based language translation unit in South Africa and by health educators and senior
clergy experienced in translating religious and government documents from English into Luo/
Acholi. To ensure conceptual and cultural equivalence, cancer experts (SA = 4, Uganda = 4)
fluent in both English and the local language scored tool items from 1(poor) to 4(excellent) on
Development and validation of the AWACAN tool
PLOS ONE | https://doi.org/10.1371/journal.pone.0220545 August 6, 2019 5 / 14
equivalence of meaning comparing the English and locally translated version. For items that
were scored as 3 or less, experts were asked to suggest changes. Cognitive interviews using
think-aloud methodology were carried out with local-language speaking community partici-
pants using the IsiXhosa version (SA, n = 8) and the Luo/Acholi version (Uganda, n = 10) to
assess whether questions were understood as intended. Participants were recruited from pri-
mary health care clinics at urban and rural sites in South Africa and Uganda. Interviews were
conducted by trained local interviewers conversant in the local language.
This process resulted in minor changes; these included correction of spelling errors,
changes in phrasing to language used more commonly in communities, and inclusion of
words that had been inadvertently omitted in the translation.
Results
In total there were 139 community (SA n = 72, Uganda n = 67), 23 non-medical staff and 20
cancer expert participants who completed the validation studies (Step 3). Table 1 outlines the
socio-demographic characteristics of the participant groups.
Test-retest reliability
There was no loss-to follow up between the first and second round of interviews. The percent-
age of agreement for responses to the socio-demographic questions was high (> 96% for all
questions and total agreement for 8 of the 11 socio-demographic variables). Kappa scores for
the socio-demographic questions ranged between 0.83 and 1.00.
Table 2 shows the agreement, the Brennan and Prediger prevalence-adjusted and bias-
adjusted kappa and the unadjusted kappa scores in brackets for items relating to awareness,
help-seeking behavior and confidence. For breast cancer, the adjusted kappa co-efficient ran-
ged from 0.57 to 1.0 with one item (‘self-medicate’) showing moderate agreement and other
items indicating substantial or almost perfect agreement. For cervical cancer, the adusted
kappa coeeficients ranged from 0.65–1.0 i.e. all showed substantial or higher agreement. Unad-
justed kappa co-efficient (shown in brackets) ranged from -0.06 to 1.0 for both cancers.
Table 1. Socio-demographic characteristics of participants.
Community SA N = 72 Community Uganda N = 67 Non-medical staff N = 23 Cancer experts N = 20
Median age in years (IQR) 40.5 (30–53) 40.0 (21–73) 52.0 (41–55) 49.0 (41–54)
Highest educational level completed
No formal schooling 1 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Primary 8 (11.1%) 17 (25.4%) 0 (0.0%) 0 (0.0%)
Secondary 57 (79.2%) 50 (74.6%) 4 (17.4%) 0 (0.0%)
More than secondary 6 (8.3%) 0 (0.0%) 19 (82.6%) 19 (100.0%)�
Employed
Yes 29 (40.3%) 21 (31.3%) 23 (100.0%) 20 (100.0%)
Current relationship status
Married/Living with a partner 30 (41.7%) 30 (44.8%) 13 (56.5%) 15 (75.0%)
Single 33 (45.8%) 4 (6.0%) 8 (34.8%) 4 (21.1%)
Separated/Divorced 6 (8.3%) 12 (17.9%) 2 (8.7%) 0 (0.0%)
Widowed 3 (4.2%) 19 (28.4%) 0 (0.0%) 0 (0.0%)
Did not answer 0 (0.0%) 2 (3.0%) 0 (0.0%) 1 (5.0%)
SA: South Africa
IQR: interquartile range
� 1 missing record
https://doi.org/10.1371/journal.pone.0220545.t001
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Test-retest reliability was moderate for knowledge of known risk factors, good for symp-
toms and excellent for lay beliefs of breast cancer (Table 3). For cervical cancer, test-retest reli-
ability was moderate for known risk factors, lay beliefs and the symptom domain.
Construct validity
A high proportion of community participants had heard of breast and cervical cancer (90%
and 84% respectively) and there were no statistically significant differences between experts
and community members for these items (1-sided Fischer’s exact test p value = 0.184 and
0.222 respectively).
For breast cancer, community participant and expert scores were significantly different for
knowledge of evidence-based risk factors and risk lay beliefs but similar for breast cancer
symptoms (Table 4). There was clear discrimination between the community participants and
cancer experts’ knowledge of evidence-based risk factors and symptoms of cervical cancer.
Knowledge did not differ significantly for the 1 cervical cancer risk lay belief (p = 0.444).
Internal reliability
The internal reliability for the breast cancer knowledge questions was good with KR-20
values> 0.7 for the known risk factors, lay belief and symptom subscales (Table 5). For
Table 2. Test-retest reliability of awareness, help-seeking behavior and confidence.
Breast cancer Cervical cancer
% Agreement Adjusted Kappa (Unadjusted
Kappa)
% Agreement Adjusted Kappa (Unadjusted
Kappa)
Heard of/know someone with breast/cervical cancer
Ever heard of breast/cervical cancer 100 N/A–all yes 100 N/A all yes
Know someone with breast/cervical cancer 95.7 0.91 (0.65) 95.7 0.91 (0.89)
Help-seeking behavior for breast/cervical symptom
Ignore it 95.7 0.91 (0.00) 87.0 0.74 (-0.06)
Hope it would go away 73.9 0.61 (0.50) 82.6 0.65 (0.65)
Self-medicate 78.3 0.57 (0.16) 95.7 0.91 (0.88)
Tell someone close to me 100 1.0 (1.0) 87.0 0.80 (0.52)
Pray for healing 100 1.0 (1.0) 100 1.0 (1.0)
Visit a traditional healer 95.7 0.91 (0.65) 95.7 0.91 (0.65)
Visit a health care facility 87.0 0.74 (-0.06) 87.0 0.74 (-0.06)
Behaviour and confidence
Ever check breasts 100 1.0 (1.0) N/A
Confidence in noticing breast/cervical change 87.0 0.74 (0.51) 82.6 0.74 (0.56)
Ever seen a healthcare practitioner for breast/cervical
change
91.3 0.83 (0.83) 87.0 0.80 (0.68)
Ever seen a traditional healer for breast/cervical change 87.0 0.74 (0.74) 87.0 0.74 (0.69)
https://doi.org/10.1371/journal.pone.0220545.t002
Table 3. Test-retest reliability of knowledge domains (N = 23).
Breast cancer Cervical cancer
Test-retest reliability ICC p-value Test-retest reliability ICC p-value
Known risk factors 0.70 <0.001 0.71 <0.001
Risk lay beliefs 0.91 <0.001 0.75 <0.001
Symptoms 0.77 <0.001 0.50 0.001
ICC: intraclass correlation
https://doi.org/10.1371/journal.pone.0220545.t003
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cervical cancer the KR-20 for the known risk factors subscale was lower (0.60). Cervical cancer
risk factors items with a very low item-to-total correlation were: HPV (0.18), using birth con-
trol/family planning pills for more than 5 years (0.13), not going for regular screening (0.09).
Internal reliability for the cervical cancer symptom questions was good (0.80).
Final AWACAN tool
Following assessment of reliability and validity, further adjustments to phrasing of some items
were made to improve clarity. The number of questions related to barriers to seeking care was
reduced (7 questions removed) as interviewers noted that participants found that this section
was too long. In addition the wording of questions was changed to better indicate that these
were barriers personally experienced by the respondent. Responses to open questions on risk
factors and symptoms were reviewed to identify additional lay beliefs.
The final version of the AWACAN tool has a total of 115 items:
i. 12 socio-demographic questions;
ii. 50 breast cancer symptom, risk factor awareness, confidence and help-seeking measures
Table 4. Comparison of expert and community participant knowledge.
Breast Cancer Cervical Cancer
Knowledge domain Community Experts p-value Community Experts p-value
Max. score n n Max. score n n
Mean Mean Mean Mean
sd sd sd sd
Known risk factors 13 124 17 <0.001# 10 116 15 0.003#
5.2 11.1 6.7 8.3
2.8 2.1 1.9 1.8
Risk lay beliefs 7 125 18 <0.001# 1 116 16 0.444#
2.5 6.1 0.8 0.9
1.7 1.1 0.4 0.3
Symptoms 15 139 18 0.066# 11 138 17 0.001##
12.7 13.9 7.6 8.9
2.7 1.8 2.3 1.3
Max.: Maximum
sd: standard deviation
#P values for T-test for groups with equal variances
## P values for T-test for groups with unequal variances
https://doi.org/10.1371/journal.pone.0220545.t004
Table 5. Internal reliability of the AWACAN tool.
Breast Cancer Cervical cancer
Knowledge
domain
No. of items per
domain
No. of
responses
Kuder-Richarson coefficient of
reliability
No. of items per
domain
No. of
responses
Kuder-Richarson coefficient of
reliability
Known risk
factors
13 164 0.78 10 154 0.60
Risk lay beliefs 7 166 0.73 1 154 N/A#
Symptoms 15 180 0.79 11 179 0.80
#N/A, not applicable as includes only 1 item.
https://doi.org/10.1371/journal.pone.0220545.t005
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• 2 introductory questions
• 1 open question on risk factors
• 13 closed prompted evidence-based risk factor questions
• 6 closed prompted questions on lay beliefs related to risk (can serve as distractor items)
• 1 open question on symptom awareness
• 15 closed prompted questions on symptom awareness items. Images of symptoms as they
would appear on dark-skinned women were added for 3 items: change in the position of
the nipple, pilling in of the nipple, and dimpling of the breast skin
• 1 closed prompted question on symptom lay belief (can serve as distractor item)
• 7 items related to help-seeking behaviour
• 4 items on confidence in relation to breast changes
iii. 41 cervical cancer symptom, risk factor awareness, confidence and help-seeking measures
• 2 introductory questions
• 1 open question on risk factors
• 11 closed prompted evidence-based risk factor questions
• 4 closed prompted questions on lay beliefs related to risk (can serve as distractor items)
• 1 open question on symptom awareness
• 11 closed prompted questions on symptom awareness items
• 1 closed prompted question on symptom lay belief (can serve as distractor item)
• 7 items related to help-seeking behaviour
• 3 items on confidence in relation to detecting cervical cancer signs/symptom
iv. 12 items on barriers to seeking care for breast and cervical cancer
See S1 Appendix The AWACAN tool for breast and cervical cancer English version and S2
Appendix Images of breast cancer changes. The English, isiXhosa and Acholi versions of the
tool as well as the breast images are available at www.awacan.online
Discussion
To our knowledge this is the first validated tool measuring breast and cervical cancer symptom
and risk factor awareness, lay beliefs, confidence in appraising potential symptoms, help seek-
ing behaviour and barriers to care in SSA populations. The AWACAN tool follows a similar
format to the BCAM and CCAM [25,26]. Knowledge of risk factors and symptoms are first
assessed with open-ended questions followed by a prompted checklist of known factors. Par-
ticipants are not permitted to revise open-ended responses. This sequence of questioning
allows respondents an opportunity to describe their own views without the possibility of guess-
ing or being limited by the pre-existing options of the prompted questions that follow.
Although responses to open-ended questions are more time-consuming to analyze compared
to prompted questions, they can provide insights into terms and phrases commonly used to
describe risk and symptoms which could assist in providing culturally relevant and easily
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understood language for interventions. Open-ended responses can also assist in identifying
locally relevant risk and symptom lay beliefs.
Our AWACAN tool performed well in terms of test-retest reliability indicating that the
questions are stable over time. Most socio-demographic, help-seeking behaviour and confi-
dence items achieving substantial or higher adjusted kappa coefficients and all knowledge sub-
scales showing moderate or higher reliability as measured by the ICC.
The AWACAN tool discriminated well between the expert and community level knowledge
of breast cancer risk factors and risk lay beliefs. However, breast symptom knowledge was sim-
ilar between these two groups. This could be a result of greater public awareness of breast
symptoms, which is a focus of many breast awareness campaigns. Knowledge of cervical can-
cer items risk factors and symptoms was significantly higher in cancer experts compared to
community participants, establishing construct validity for these subscales. At the stage of psy-
chometric testing we only had one cervical cancer risk lay belief and although experts were bet-
ter able to identify this lay belief the difference was not statistically different. Using responses
from the open-ended questions we were able to identify additional lay belief items.
Internal reliability was good for our breast cancer questions, with all knowledge domains
achieving a KR-20 above the recommend cut-off value of 0.7. Internal reliability was also high
(KR-20 = 0.8) for the cervical cancer symptom domain, but lower (KR-20 = 0.6) for the subsec-
tion on risk factors. The three risk factor items contributing to this low internal reliability
(HPV, use of birth control/family planning pills, not going for regular screening) were retained
in the final tool on grounds of content validity.
After establishing good validity for the English version of the tool, it was translated into two
2 local languages (isiXhosa and Acholi), taking into account conceptual and cultural equiva-
lence. In addition to these translations, there are some other important differences between
our validated AWACAN tool and the BCAM and CCAM tools. Our tool includes additional
prompted items on symptom and risk lay beliefs that were identified from the literature [27],
and in responses to the open questions administered during the AWACAN development and
validation process. These questions provide insights into lay beliefs that may need to be
addressed when developing SSA-relevant and targeted interventions to improve timely diag-
nosis in these populations. In addition, the lay belief questions which are interspersed between
known risk factors and symptoms serve as distractor items. For effectiveness, distractor items
should represent incorrect responses that study participants could be expected to produce and
avoid obviously implausible responses [41]. We were able to identify a number of breast and
cervical cancer risk lay beliefs, but only one breast and one cervical cancer symptom lay belief.
When the AWACAN tool is used in future studies, evaluation of open responses could assist
in identifying additional locally relevant symptom distractor items.
Based on the recommendation of Wachira et al [27], we developed images for 3 breast can-
cer symptoms on dark-skinned women to be used with the tool. We believe that this is an
important addition to cancer awareness measurement tools in our context. Further, these
images can be used in awareness raising interventions. The AWACAN tool also includes sim-
ple explanations for terms that were not well understood by participants in our setting (e.g.
menopause). Compared to the CAM tools our final tool does not include age-related risk fac-
tors as these were poorly understood by community participants and also received a low CVI
score from experts.
The BCAM and CCAM tools make use of Likert scales, which call for a graded response to
a series of statements about risk and confidence. Likert scales are widely used in surveys, how-
ever studies have reported challenges such as difficulty in understanding graded response
options, skipping questions or bias toward either the midpoint or extreme options [42,43].
During cognitive testing we noted that participants in both SA and Uganda had difficulty
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understanding the Likert-type scales used in the CAM tools. Questions were thus modified in
our tool to allow for simpler response options.
Understanding women’s help-seeking behaviour and potential barriers to care are critical
to informing efforts to improve timely diagnosis of these cancers. The ABC and CAM tools
includes measures of barriers to care and help-seeking behaviour relevant in high-income set-
ting [23,25,26]. We included additional questions to reflect the different realities in the SSA
context. For example, traditional healers are often consulted for health-related issues in SSA
[44] and are included in our measures. We reduced the number of questions on barriers to
seeking care in the final tool and made substantial changes to the wording of the remaining
questions. Validity of this domain of our questionnaire will be further evaluated in future use
of the tool and attention paid to context-specific variations.
Over the past few decades, there has been an increasing recognition that a holistic and com-
prehensive approach to women’s health is central to sustainable development [45,46]. We
developed the AWACAN tool so that the two most common cancer in females in SSA can be
addressed in one study to maximise data collection from women. However the tool can also be
used for either breast or cervical cancer assessments alone.
A limitation of our study was the difference in mode of delivery to the cancer experts (online)
versus other participants (face-to-face) during the validation process. We designed the online tool
so that experts were unable to return to previous pages to change responses. However, we recog-
nize that experts could have searched the internet or consulted elsewhere before completing the
tool online. We used Classical Test Theory to assess reliability and validity of the AWACAN tool.
An alternative would be to use Item Response Theory [47,48]. However this would have required
an extremely large sample size given the number of items in the questionnaire. Classical Test The-
ory was used in the development of the CAM and is adequate for this developmental phase, espe-
cially in a context with limited resources. The isiXhosa and Acholi versions of the AWACAN tool
have recently being used in a cross-sectional study and further psychometric testing with these
local language versions of the tool are being undertaken. In addition we intend to administer and
assess validity of the AWACAN tool in other SSA countries. Important and interesting differences
are likely to be identified with this broader administration.
We have demonstrated that the breast and cervical AWACAN tool has evidence of reliabil-
ity and validity and is ready to be used as a measure of risk factor and symptom awareness, lay
beliefs, help seeking behavior and barriers to care for the two leading causes of cancer morbid-
ity among women in SSA.
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